erythropoietin in management of neonatal hypoxic ischemic encephalopathy

Conditions: Hypoxic-Ischemic Encephalopathy

Summary: perinatal hypoxic-ischaemic encephalopathy occurs in one to three infants per 1000 term births, and up to 12 000 infants are affected each year in the united state of america. hypoxic ischemic encephalopathy is not preventable in most cases, and therapies are limited. hypothermia improves outcomes and is the current standard of care. yet clinical trials suggest that 44% to 53% of infants who receive hypothermia will die or suffer moderate to severe neurological disability. therefore, novel neuroprotective therapies are urgently needed to further reduce the rate and severity of neurodevelopmental disabilities resulting from hypoxic ischemic encephalopathy. erythropoietin is a novel neuroprotective agent, with remarkable neuroprotective and neuroregenerative effects in animals. rodent and primate models of neonatal brain injury support the safety and efficacy of multiple erythropoietin doses for improving histological and functional outcomes after hypoxia-ischaemia.

the cellular mechanisms by which erythropoietin exert neuroprotection are complex and not completely understood. in the acute period after hypoxia ischaemia, erythropoietin signaling in the brain induces several neuroprotective mechanisms. in addition to its anti-apoptotic and anti-inflammatory properties, erythropoietin also increases antioxidant activities and reduces excitotoxic cell injury. in addition to its acute effects, erythropoietin stimulates growth factor release, enhances neurogenesis and angiogenesis, and promotes long-term repair and plasticity. thus, erythropoietin provides neuroprotective and trophic effects that last well beyond the acute period of injury erythropoietin .enhances neurogenesis and directs multipotent neural stem cells to differentiate toward a neuronal cell fate. in a clinical trial performed in china, zhu et al. studied 167 neonates with of hypoxic ischemic encephalopathy that were randomized to receive erythropoietin (300-500u/kg) or placebo every second day for 2 weeks. the first dose of erythropoietin was given within 48 hours of delivery. compared with placebo-treated infants, infants that received erythropoietin were less likely to die or have moderate to severe disability at 18 months of age (44% vs 25%, p=0.02). similarly, elmahdy et al. studied 30 infants with hypoxic ischemic encephalopathy who were randomized to receive five daily doses of 2500 units/kg erythropoietin, or placebo, with the first dose given within 24 hours of delivery. the erythropoietin-treated infants demonstrated improved electroencephalography backgrounds, reduced biomarkers of oxidative stress after 2 weeks, and improved neurodevelopment at 6 months of age compared with placebo treated infants.

Eligibility criteria:
inclusion criteria: 1. ≥ 36 weeks of gestational age. 2. whole body cooling within 6 hours after birth. 3. perinatal depression based on at least one of the following: 1. apgar score \< 5 at 10 minutes. 2. need for resuscitation at 10 minutes. 3. ph \< 7.1 in cord and base deficit ≥ 15 mmol/l. 4. moderate or severe encephalopathy according to sernat and sernat staging. exclusion criteria: 1-admitted after 24 hour of birth. 2-birth weight \< 1800 g (e.g., intrauterine growth restriction) 3-genetic or congenital condition that affects neurodevelopment. 3-torch infection and neonatal sepsis. 4-complex congenital heart disease. 5-severe dysmorphic feature . 6-microcephaly:head circumference \< 2 stander deviations below mean for gestational age. 7-polycythemia (hematocrit \> 65%). 8-premature rupture of membrane or chorioamnionitis.